Detection of immunogenic cell death and its relevance for cancer therapy

Chemotherapy, radiation therapy, as well as targeted anticancer agents can induce clinically relevant tumor-targeting immune responses, which critically rely on the antigenicity of malignant cells and their capacity to generate adjuvant signals. In particular, immunogenic cell death (ICD) is accompanied by the exposure and release of numerous damage-associated molecular patterns (DAMPs), which altogether confer a robust adjuvanticity to dying cancer cells, as they favor the recruitment and activation of antigen-presenting cells. ICD-associated DAMPs include surface-exposed calreticulin (CALR) as well as secreted ATP, annexin A1 (ANXA1), type I interferon, and high-mobility group box 1 (HMGB1). Additional…

• UD
  U.S. Department of Defense

  Award: BC180476P1
• LA
  Leukemia and Lymphoma Society
• AP
  Association pour la Recherche sur le Cancer
• SF
  Seerave Foundation
• E
  E-Rare
• EC
  European Commission
• AN
  Agence Nationale de la Recherche

  Award: E-Rare-2
• FL
  Fondation Leducq
• IN
  Institut National de la Santé et de la Recherche Médicale
• FP
  Fondation pour la Recherche Médicale
• LC
  Ligue Contre le Cancer
• IU
  Institut Universitaire de France
• IN
  Institut National Du Cancer
• IG
  Institut Gustave-Roussy
• ER
  European Research Area Network on Cardiovascular Diseases
• WC
  Weill Cornell Medical College
• SU
  Stand Up To Cancer

  Award: ZP-6177
• HF
  High-end Foreign Experts Recruitment Plan of China

  Awards: GDW20171100085, GDW20181100051, GDW20171100085 and GDW20181100051
• LI
  Labex Immuno-Oncology